FDA 21 CFR Part 11 vs REACH
FDA 21 CFR Part 11
FDA regulation for trustworthy electronic records and signatures
REACH
EU regulation for chemical registration, evaluation, authorisation, restriction.
Quick Verdict
FDA 21 CFR Part 11 ensures electronic records' trustworthiness for US life sciences, while REACH mandates chemical risk management for EU market access. Companies adopt Part 11 for FDA compliance and digitized GxP, REACH to legally supply substances and avoid market bans.
FDA 21 CFR Part 11
21 CFR Part 11: Electronic Records; Electronic Signatures
Key Features
- 1. Establishes equivalency criteria for electronic records to paper
- 2. Mandates secure, time-stamped audit trails for changes
- 3. Requires unique, linked, non-repudiable electronic signatures
- 4. Enforces access, authority, operational, and device checks
- 5. Distinguishes risk-based controls for closed/open systems
REACH
Regulation (EC) No 1907/2006 on REACH
Key Features
- Industry bears burden for chemical hazard data generation
- Registration mandatory above 1 tonne/year per entity
- SVHC Candidate List triggers supply-chain notifications
- Authorisation regime with sunset dates for high-concern substances
- Annex XVII lists EU-wide restrictions and bans
Detailed Analysis
A comprehensive look at the specific requirements, scope, and impact of each standard.
FDA 21 CFR Part 11 Details
What It Is
FDA 21 CFR Part 11 is a U.S. federal regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The approach is risk-based, with narrow scope per 2003 guidance emphasizing reliance on electronic records.
Key Components
- **Subpart AScope, definitions (closed/open systems).
- **Subpart BControls (§11.10 closed systems: validation, audit trails, access; §11.30 open systems: encryption/digital signatures).
- **Subpart CSignature rules (§11.100-11.300: uniqueness, multi-component controls).
- Core principles: authenticity, integrity, non-repudiation; no formal certification, but inspection readiness required.
Why Organizations Use It
Mandated for electronic records in pharma, devices, biologics; mitigates enforcement risks (warnings, holds); enables paperless operations, data integrity, faster inspections; builds stakeholder trust via validated systems.
Implementation Overview
Risk-based CSV (GAMP5): scope records, validate (IQ/OQ/PQ), implement controls, train, change control. Applies to life sciences globally; phased (6-24 months); ongoing audits, no external cert but FDA inspections.
REACH Details
What It Is
REACH (Regulation (EC) No 1907/2006) is a directly applicable EU regulation governing Registration, Evaluation, Authorisation and Restriction of Chemicals. Its primary purpose is to ensure a high level of protection for human health and the environment from chemical risks by shifting responsibility to industry for generating and managing safety data. It adopts a risk-based lifecycle approach covering substances, mixtures, and articles.
Key Components
- Four pillars: Registration, Evaluation, Authorisation, Restriction.
- Detailed annexes (e.g., Annex XIV for Authorisation List, Annex XVII for Restrictions).
- Core principles: industry-led data generation, supply-chain communication via Safety Data Sheets (SDS), tonnage-based requirements.
- No certification; compliance via dossier submission to ECHA and national enforcement.
Why Organizations Use It
- Legal obligation for EU market access (mandatory for >1 tonne/year importers/manufacturers).
- Mitigates fines, market bans, recalls; enhances risk management.
- Drives substitution, innovation, supply-chain transparency; builds stakeholder trust.
Implementation Overview
- Phased: gap analysis, substance inventory, dossier preparation, monitoring.
- Applies to chemical-dependent firms across EU/EEA; complex for globals.
- Continuous audits, no formal certification but inspection readiness essential.
Key Differences
| Aspect | FDA 21 CFR Part 11 | REACH |
|---|---|---|
| Scope | Electronic records/signatures trustworthiness in FDA-regulated activities | Chemical substance registration, evaluation, authorisation, restriction |
| Industry | Life sciences, pharma, medical devices (US-focused) | Chemicals, manufacturing, importers across all sectors (EU/EEA) |
| Nature | US FDA regulation with enforcement discretion | Mandatory EU regulation with national enforcement |
| Testing | Risk-based system validation, IQ/OQ/PQ | Hazard/exposure testing by tonnage bands, dossier submission |
| Penalties | Warning letters, product holds, CGMP violations | Fines, market bans, effective/proportionate/dissuasive penalties |
Scope
Industry
Nature
Testing
Penalties
Frequently Asked Questions
Common questions about FDA 21 CFR Part 11 and REACH
FDA 21 CFR Part 11 FAQ
REACH FAQ
You Might also be Interested in These Articles...

Beyond the Checkbox: Why Maturity Assessments are the Secret to Sustainable Compliance
Discover why maturity assessments beat binary compliance checks by uncovering hidden gaps and enabling continuous improvement for sustainable success. Read now!

Thailand PDPA Implementation Guide: Subordinate Regulations for 72-Hour Breach Reporting and Cross-Border Transfers (2022-2024 Rules)
Step-by-step Thailand PDPA guide: 72-hour breach notifications, cross-border transfers (2022-2024 rules). Risk checklists, GDPR templates avoid THB 5M fines. Mu

NIST CSF 2.0: Key Enhancements and How They Address Evolving Cyber Threats
Explore NIST CSF 2.0 updates: Govern function, supply chain security, SME playbooks for ransomware & AI threats. Boost your cyber defenses now!
Run Maturity Assessments with GRADUM
Transform your compliance journey with our AI-powered assessment platform
Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.
Explore More Comparisons
See how FDA 21 CFR Part 11 and REACH compare against other standards